Clinical Trial Update: Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide [EARLY_Phase 1]

View source ↗

Summary

Clinical trial update on an early-phase haploidentical transplant approach for chronic granulomatous disease using alemtuzumab, busulfan, total body irradiation…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Granulomatous Disease

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• BUSULFAN (Busulfan)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Chronic Granulomatous Disease | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING